Targeting the mevalonate pathway with statins overcomes acquired resistance to KRASG12C inhibitors in non-small cell lung cancer

Abstract The emergence of covalent KRASG12C inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC), yet acquired resistance remains a major clinical challenge. Here, we systematically identified statins as potent agents capable of overcoming acquired resistance to KRASG12C...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Weihao Lin, Qi-an Chen, Yannan Yang, Yibo Gao, Jie He
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2026-06-01
Rangatū:	Experimental Hematology & Oncology
Ngā marau:	KRASG12C inhibitor Acquired resistance Mevalonate pathway Statin Non-small cell lung cancer
Urunga tuihono:	https://doi.org/10.1186/s40164-026-00797-x
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!